Fig. 1. HLA-G isoforms, monomers and dimers
A. The alternative splicing of a unique primary transcript yields 7 protein isoforms: truncated isoforms are generated by excision of one or two exons encoding globular () domains, whereas translation of intron 4 (i4) or intron 2 (i2) yields soluble isoforms that lack the transmembrane domain. B. HLA-G molecules can form homodimers through the generation of Cys42-Cys42 disulfide bonds.
In addition, a soluble HLA-G1 isoform (shed HLA-G1) can be generated by the membrane HLA-G1 proteolytic cleavage that is dependent on metalloproteinase activity (Park et al., 2004) , and is regulated by Nitric Oxide (NO) concentration (Diaz-Lagares et al., 2009) and Tumor Necrosis Factor (TNF)-/NFkB pathway activation (Zidi et al., 2006) . Soluble and membrane-bound HLA-G isoforms have similar functions. HLA-G1, HLA-G5, and shed HLA-G1 are the most described isoforms in healthy tissues (Paul et al., 2000) and their structure is similar to that of classical HLA class I molecules: a heavy chain of three globular domains non-covalently associated with 2-microglobulin (2m) and a nona-peptide (Clements et al., 2005) . The other HLA-G isoforms contain the 1 domain but lack one or two of the other globular domains, and are not associated with 2m and the peptide. The presence of the 3 domain is important to HLA-G functions since it represents a binding site for HLA-G receptors (Clements et al., 2005; Clements et al., 2007) .
HLA-G possesses two unique cysteine residues, in position 42 of the 1 domain and in position 147 of the 2 domain. Through these residues, HLA-G may dimerize by intramolecular disulfide bonds (Boyson et al., 2002) . Membrane-bound or soluble HLA-G dimers were detected both in vitro and in vivo (Apps et al., 2007; Boyson et al., 2002; Gonen-Gross et al., 2005) (Fig. 1B) . Dimerization of HLA-G is one of its key features since dimers bind to HLA-G receptors with higher affinity and slower dissociation rates compared to monomers (Shiroishi et al., 2006a) and, as a consequence, dimers, but not monomers, carry most of the HLA-G functions (Gonen-Gross et al., 2003; Li et al., 2009 ).
HLA-G acts through three inhibitory receptors: immunoglobulin-like transcript (ILT)2 (CD85j/LILRB1), ILT4 (CD85d/LILRB2), the killer cell immunoglobulin-like receptor (KIR)2DL4 (CD158d), and the co-receptor CD8 (Colonna et al., 1997; Colonna et al., 1998; Rajagopalan and Long, 1999) (Fig. 2) .
Fig. 2. HLA-G receptors
Inhibitory receptors known to bind HLA-G. Basic structural organization and expression patterns are shown. The HLA-G structural configuration that these receptors are known to bind are indicated as '+' (reported binding) and '-' (reported absence of binding or minor binding).
ILT2 is expressed by B cells, some T cells (both CD4 + and CD8 + ), a sub-population of NK cells, and all monocytes/Dendritic Cells (DCs) (Colonna et al., 1997) , whereas ILT4 is only expressed by mono/macrophages and DCs (Colonna et al., 1998) . KIR2DL4 is expressed by some CD8 + T and NK cells (Goodridge et al., 2003) .
Even if ILT2 and ILT4 recognize other HLA Class I molecules, HLA-G is their ligand of highest affinity and they bind HLA-G dimers even more strongly (Shiroishi et al., 2006a; Shiroishi et al., 2003) . ILT2 and ILT4 can recognize different HLA-G structures: ILT2 binds only 2m-associated HLA-G1/G5 isoforms, whereas ILT4 also recognizes their 2m-free counterparts (Gonen-Gross et al., 2005; Shiroishi et al., 2006b ). Finally, significantly higher expression of ILT2 was necessary for efficient HLA-G tetramer binding, suggesting that this www.intechopen.com interaction may have relatively lower affinity compared to that of ILT4 (Allan et al., 1999) . Interestingly, HLA-G can directly influence the expression rate of its receptors both at mRNA level and at the protein level . Thus, HLA-G is unique in its ability to be expressed in different isoforms and to act through inhibitory receptors.
Mechanisms underlying HLA-G expression
Even if theoretically any tissue might express HLA-G, its physiological expression is restricted to few tissues such as trophoblasts, thymic epithelium, cornea, MSC and pancreatic -cells (Carosella, 2011) . Nonetheless, in pathological conditions, HLA-G expression can be induced and/or up-regulated. So far the reason why HLA-G can be expressed in some, but not in all tissues has not been fully elucidated. However, several factors such as immune-modulatory cytokines and hormones, were described to potentially affect transcriptional mechanisms responsible for HLA-G expression . In contrast to classical HLA class I molecules, HLA-G expression is not influenced by the transcription factor NF-kB (Gobin et al., 1998) or by classical pro-inflammatory cytokines such as Interferon (IFN)- (Gobin et al., 1999) , since responsive elements for IFN- are missed in HLA-G promoter (Gobin et al., 1999; Steimle et al., 1995) . In contrast, HLA-G transcriptional rate is increased by the presence of a number of anti-inflammatory cytokines including IFN- , Interleukin (IL)-4, IL-5, IL-6 (Deschaseaux et al., 2011), and IL-10 (Moreau et al., 1999) and can be modulated by Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) (Onno et al., 2000; Yang et al., 1996) , Transforming Growth Factor (TGF)-, or Granulocyte Colony-Stimulating Factor (G-CSF).
In addition to cytokines, hormones like glucocorticoids (dexamethasone) and progesterone were shown to increase the secretion of both HLA-G5 and HLA-G6 by trophoblasts (Akhter et al., 2011; Moreau et al., 2001; Yie et al., 2006a; Yie et al., 2006b) . HLA-G expression can be also influenced by Adenosine Triphosphate (ATP) and by the tryptophan catalayzing enzyme indoleamine 2 3-dioxygenase (IDO). ATP acts as a potent inhibitor of HLA-G1 and HLA-G5 production from LPS-activated PBMCs via down-regulation of IL-10 ( Rizzo et al., 2009) . IDO, known to be involved in the generation of tolerogenic microenvironments by tryptophan depletion and in the generation of T regulatory (Treg) cells (Chung et al., 2009; Munn et al., 2002) , was shown to differentially modulate HLA-G expression in monocytes and myeloid DCs. IDO blocked HLA-G cell-surface expression on monocytes (GonzalezHernandez et al., 2005) , but it induced HLA-G expression and shedding in myeloid DCs (Lopez et al., 2006) . Overall, a number of immune mediators can influence HLA-G expression. It has to be taken in account that these molecules can be up-regulated in conditions, such as inflammation, in which HLA-G expression is needed to control or dampen the immune response. I n a d d i t i o n t o s o l u b l e f a c t o r s , i t h a s b e e n r e c e n t l y r e p o r t e d t h a t " t r a n s i e n t " H L A -G expression can be acquired via trogocytosis, a cell-to-cell contact-dependent uptake of membranes and associated molecules from one cell by another (reviewed in (Davis, 2007; LeMaoult et al., 2007a) . Trogocytosis of HLA-G was shown for activated CD4 + and CD8 + T cells , activated NK cells (Caumartin et al., 2007) , and monocytes (HoWangYin et al., 2011) . For CD4 + T cells, the most important consequence of HLA-G acquisition, is that the newly-expressing cells became transiently tolerogenic (LeMaoult et al., 2007a) , as discussed below. Thus, trogocytosis generates HLA-G positive cells, which display, but do not express HLA-G. The ability of different cells to transiently acquire HLA-G expression broadens the immuno-modulatory activity of HLA-G.
HLA-G immunological function
The functions of HLA-G are exclusively oriented towards immune inhibition and tolerance. HLA-G exerts its inhibitory functions on several immune cells through direct binding to the inhibitory receptors ILT2, ILT4, and KIR2DL4 (Shiroishi et al., 2006b ).
Short-term immuno-modulation mediated by HLA-G
HLA-G:ILT2 interaction modulates NK cell activity (Rouas-Freiss et al., 1997) . HLA-Gexpressing target cells are indeed resistant to the lysis mediated by NK cells (Riteau et al., 2001) . Although the mechanisms underlying this effect are not completely elucidated, it has been recently defined that HLA-G:ILT2 interaction disrupts the immunological synapse (IS), a supramolecular structure responsible for both T and NK cell activation and function (Favier et al., 2010) , leading to inhibition of NK cytolysis. HLA-G binds to KIR2DL4 on NK cells (Shiroishi et al., 2006b ). However, it still remains unclear which are the effects mediated by this interaction. Ligation of KIR2DL4 activates cytokine production but not cytotoxicity (Rajagopalan et al., 2001) , and it has been recently proposed that activation of KIR2DL4 by soluble HLA-G activates a pro-inflammatory/pro-angigenic responses, consistent with a role in promoting vascularization during early pregnancy (Rajagopalan et al., 2006) . HLA-G can also bind CD8, which is expressed by a subpopulation of NK cells leading to Fas ligand expression, and induction of apoptosis (Contini et al., 2003) .
The interaction between HLA-G and CD8 + T cells impairs the antigen-specific cytotoxic T lymphocyte (CTLs) activity (Le Gal et al., 1999) . HLA-G has a dose-dependent effect on the generation of allo-CTL responses, while it seems to not affect pre-existing allo-CTLs (Kapasi et al., 2000) . Furthermore, during later stages of T cell activation, HLA-G:CD8 interaction promotes TCR-independent apoptosis of CD8 + T cells through the same mechanisms described for NK cells (Fournel et al., 2000) .
During the early phase of CD4 + T cell activation, HLA-G:ILT2 interaction induces a cell cycle blockade at the G1 phase (Bahri et al., 2006) , and inhibits allo-reactive T-cell proliferation (Naji et al., 2007a) . Interestingly, it has been proposed that HLA-G isoforms have different impact on the cytokine secretion profile of CD4 + T cells. HLA-G1 was indeed shown to promote T helper (h)2 polarization of naïve T cells (Kanai et al., 2001b; Kapasi et al., 2000) whereas HLA-G5 induces tumor necrosis factor (TNF)-, IFN-, and IL-10 ( Kanai et al., 2001a) . Morandi et al. recently described that HLA-G5 has an additional effect on CD4 + T cells since it down-regulates expression and function of CCR2, CXCR3, and CXCR4 on different subsets of activated CD4 + T cells, impairing their migratory capability (Morandi et al., 2010) .
The immunological functions of HLA-G on B cells are poorly described. It has been shown that in patients who underwent renal transplantation, serum levels of soluble HLA-G are negatively associated with anti-HLA antibodies and with graft rejection, suggesting that soluble HLA-G may possibly act to inhibit the immune humoral responses against HLA (Qiu et al., 2006) . Further investigation is needed to better highlight the role of HLA-G in modulating B cell responses.
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Myeloid antigen presenting cells (APCs) express both ILT2 and ILT4, which render them targets of HLA-G-mediated modulation. In the presence of HLA-G, myeloid APCs fail to stimulate allo-proliferative T cell responses in vitro (LeMaoult et al., 2004) and reduce NKmediated cytotoxicity (Gros et al., 2008) . Moreover, HLA-G inhibits the up-regulation of HLA Class II, CD80 and CD86 on myeloid DCs in response to LPS or allo-activation signals in vitro (Ristich et al., 2007) (Gros et al., 2008) . Thus, HLA-G inhibits the functions and differentiation of myeloid APCs, leading to improper T lymphocyte activation and to impair NK cytotoxic activity. However, HLA-G does not block myeloid APCs functions, but induces them to differentiate into tolerogenic cells. Several reports indeed show that HLA-G treatment up-regulates the expression of cytokines, chemokines, and chemokine receptors by myeloid APCs (Apps et al., 2007; Gros et al., 2008; Li et al., 2009; Liang et al., 2008) . The first evidence that HLA-G promotes the induction of tolerogenic APCs comes from studies conducted by the group of Horuzsko demonstrating that HLA-G treatment of monocytederived DCs that highly express ILT2 and ILT4 results in cells with tolerogenic-like phenotype and the potential to induce T-cell anergy (Ristich et al., 2005) . Results obtained in a murine model support this notion by showing that HLA-G inhibited maturation of DCs (Horuzsko et al., 2001 ) and that in ILT4 transgenic mice, the HLA-G:ILT4 interaction impaired DC maturation in vivo, leading to delayed skin allograft rejection (Liang et al., 2002) . Thereby, HLA-G by interacting with ILT receptors present on myeloid APCs induces their differentiation into regulatory cells.
Long-term tolerogenic properties of HLA-G
Myeloid APCs are not only the cells more sensitive to HLA-G-mediated modulation, but they also commonly express HLA-G. Myeloid APCs may express all HLA-G isoforms , but cell-surface HLA-G1 and secreted HLA-G5 have been described the most. In pathological contexts including transplantation, cancer, viral infections, and inflammatory diseases, the expression of HLA-G on myeloid cells can be up-regulated (Carosella et al., 2008) . Recently, in liver-transplanted patients, the presence of HLA-Gexpressing myeloid DCs has been correlated with tolerance and graft acceptance (Castellaneta et al., 2011) . Similarly, in cancer (reviewed in (Amiot et al., 2011) as well as in viral infections (reviewed in (Fainardi et al., 2011) , myeloid APCs expressing HLA-G were reported, and often correlated with poor clinical outcomes. Myeloid APCs not only express membrane-bound HLA-G1 but they may also secrete or shed HLA-G molecules, contributing to the generation of a tolerogenic microenvironment. Such a microenvironment may alter the functions not only of lymphocytes, but also of the HLA-G-expressing myeloid APCs themselves, in a tolerogenic feedback loop. HLA-G can indeed directly promote its expression and the expression of its receptors on myeloid APCs . Thus, myeloid APCs may be viewed as suppressor cells capable of inhibiting other immune effectors, and also of generating regulatory cells including Treg cells.
Treg cells are critical players for preservation of immune homeostasis and for establishment and maintenance of peripheral tolerance. Treg cells belonging to different T cell subsets, including CD4 + and CD8 + , NKT, and  T cells. The best characterized Treg populations are the forkhead box P3 (FOXP3)-expressing, CD4 + CD25 + Tregs (FOXP3 + Tregs) (Sakaguchi et al., 2010) , and the CD4 + IL-10-producing Tr1 cells (Akdis et al., 2004; Barrat et al., 2002; Groux et al., 1997; Roncarolo et al., 2006) . FOXP3 + Tregs and Tr1 cells are distinct populations of Treg cells that play a non-redundant role in maintaining tolerance, and are distinguished from one another by their distinct phenotype and cytokine profiling. FOXP3+ Treg cells are characterized by the constitutively-high expression of CD25 and the transcription factor FOXP3 (Sakaguchi, 2005) , and their development and function is strictly dependent on FOXP3 (Bacchetta et al., 2007; Gavin et al., 2007) . Tr1 cells can be induced in the periphery upon chronic antigen (Ag) stimulation in the presence of IL-10 ( Roncarolo et al., 2006) , and are currently identified by their unique cytokine profile consisting of high levels of IL-10, TGF-, and low levels of IL-2 and IFN-and the absence of IL-4 after stimulation (Bacchetta et al., 1994; Groux et al., 1997) . Once activated through their specific TCR, Tr1 cells secrete IL-10 and TGF- that directly inhibit effector T cell proliferation and expression of HLA class II and costimulatory molecules on APCs, which indirectly suppress effector T-cell activation. More recently, we demonstrated that Tr1 cells specifically kill myeloid cells via a Granzyme Bdependent mechanism (Magnani et al., 2011) .
HLA-G-expressing APCs were shown to be capable of priming naïve T cells to become Treg cells. Indeed, APC lines over-expressing membrane-bound HLA-G1 induced the differentiation of CD4 + and CD8 + T cells able to inhibit allogeneic responses (LeMaoult et al., 2004) . Resulting HLA-G-induced Treg cells included CD4 low and CD8 low T cells that suppress via soluble factors (Naji et al., 2007a; Naji et al., 2007b) . These results are in agreement with those obtained in patients who received a combined liver-kidney transplant, in which high plasma levels of HLA-G5 correlated with an increased percentage of suppressor T cells (Le Rond et al., 2004; Naji et al., 2007b) . They are also in line with results showing that high HLA-G5 plasma levels in the peripheral blood of stem cell-transplanted patients are associated with the expansion in peripheral blood of CD4 + CD25 + CD152 + T cells with suppressive activity (Le .
We recently identified and characterized a new subset of human DCs that arises in the presence of IL-10 and endogenously expresses cell-surface HLA-G . DC-10 are characterized by the outstanding ability to produce IL-10 and by the expression of high levels of membrane-bound HLA-G1 and other tolerogenic signaling molecules such as ILT2, ILT3, and ILT4 (Fig. 3) . DC-10 are potent inducers of adaptive allo-specific Tr1 cells . Furthermore, allergen-specific Tr1 cells can be generated in vitro by stimulating human T cells with autologous tolerogenic DC-10 pulsed with allergen . Interestingly, the expression of membrane-bound HLA-G1 and that of its receptors are upregulated by IL-10 on both DC-10 and T cells, and the expression of high levels of membrane-bound HLA-G1, ILT4, and IL-10 by DC-10 is critical to the generation of Tr1 cells by DC-10 (Rossetti et al., 2011).
HLA-G expressing regulatory cells
In addition to myeloid cells that can constitutively or transiently express HLA-G, T cells or other immune cells can express or secrete HLA-G.
A subpopulation of CD4 + HLA-G1 + and CD8 + HLA-G1 + T cells has been described (Feger et al., 2007) . They represent a small subset of peripheral blood cells in healthy individuals, but A. DC-10 are present in vivo and characterized by the expression of the surface markers CD14, CD16, CD83. They also express high levels of HLA-G1 and its receptor ILT4. B. DC-10 can be differentiated in vitro starting from the CD14+ fraction of PBMCs cultured for 7 days in the presence of GM-CSF, IL-4 and IL-10.
are increased at sites of inflammation, such as in the central nervous system of patients with neuro-inflammatory disorders and in muscle tissue in patients with idiopathic myositis (Feger et al., 2007; Huang et al., 2009a; Wiendl et al., 2005) . CD4 + HLA-G1 + T cells represent a population of naturally occurring Treg cells distinct from nTreg cells, since they lack CD25 and FOXP3 expression. HLA-G + Treg cells showed reduced proliferation in response to allogeneic (mDCs) and polyclonal stimulation (CD3/CD28), and have a cytokine profiling different from Tr1 cells. CD4 + HLA-G + and CD8 + HLA-G + Treg cells inhibit the proliferation of autologous HLA-G -T cells through HLA-G1/sHLA-G1 (Feger et al., 2007) and soluble factors, including IL-10 (Huang et al., 2009b) . A population of induced HLA-G + T cells has been also described, these allo-specific CD4 + and CD8 + T cells were shown to express HLA-G1 and to secrete HLA-G5 (Le Rond et al., 2004; Lila et al., 2001) . Moreover, we demonstrated that up-regulation of HLA-G on CD4 + T cells is critically required for DC-10 mediated induction of adoptive Tr1 cells .
Adult bone marrow MSCs can also express HLA-G and have been included in the list of regulatory cells. MSCs are multipotent cells that play an important role in tissue regeneration and also have strong immuno-modulatory properties (reviewed in (Uccelli et al., 2008) ). MSCs express low levels of HLA Class I molecules, do not express HLA class II or co-stimulatory molecules, and therefore do not induce T-cell activation. It has been demonstrated that MSCs constitutively express HLA-G5 (Selmani et al., 2009 ). Even though HLA-G expression decrease during MSCs expansion in vitro, recent studies clearly identified it as a key contributor to MSCs immune-tolerogenic functions (Nasef et al., 2007; www.intechopen.com 2008; Selmani et al., 2008) . In addition to a direct suppressive function through HLA-G5, MSCs can induce via a cell-to-cell contact mechanism CD4 + CD25 high Foxp3 + Treg cells (Selmani et al., 2008) .
HLA-G and its polymorphisms
Very few polymorphisms have been identified in the coding region of the HLA-G locus. The heavy chain encoding region exhibits 33 Single Nucleotide Polymorphisms (SNPs) but only 13 amino acid variations are observed. This peculiarity is important in determining the biological function of HLA-G, since a reduced variability leads to a limited peptide repertoire and presentation capability (Clements et al., 2005) , and can influence the polymerization rate. Moreover, the 5' Up-stream Regulatory Region (5' URR), containing the promoter, and the 3' untranslated region (UTR) exhibit numerous nucleotide variations that may influence HLA-G expression (Donadi et al., 2011; Larsen and Hviid, 2009 ) and consequently its tissue distribution in healthy and pathological conditions (Fig. 4) . Fig. 4 . HLA-G locus and its polymorphisms Schematic representation of HLA-G locus. The major polymorphisms observed at the 5'URR and at 3'UTR regions are indicated. URR: Up-stream regulatory region; UTR: Untraslated region.
5' up-stream regulatory region (URR)
Because of the presence of regulatory elements, polymorphisms at the 5' URR might have a relevant impact in the regulation of HLA-G expression (Fig. 4) . The region up-stream from the transcriptional start site of HLA-G contains 27 different polymorphisms but only 13 of them are within or very close to known transcription factor binding sites or regulatory elements (Hviid et al., 1999; Ober et al., 2003; Tan et al., 2005) . Interestingly, all the 27 polymorphisms are in strong linkage disequilibrium (LD) and define 13 unique promoter haplotypes (Ober et al., 2003; Tan et al., 2005) . Among the 5' URR polymorphisms, only the -725C/G/T single nucleotide polymorphism (SNP) has been associated with HLA-G expression. Ober et al. demonstrated that the presence of G in position -725 significantly increases HLA-G transcription rate in JEG-3 cell line (Ober et al., 2006) and, when it is present in both parents, it is significantly associated with fetal loss rate (Ober et al., 2003) .
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An additional interesting SNP located in 5' URR is the -201 A/G SNP since it resides into the enhancer A region (Hviid et al., 1999) . However, it still remains to be clarified if this polymorphism has any impact on the expression of certain HLA-G alleles.
3'untraslated region (UTR)
The exon 7 of the HLA-G locus is always absent in the mature messenger(m)RNA. Moreover, due to the presence of a stop codon in the exon 6 of HLA-G, the exon 8 is not translated. Thus, exon 8 is considered the 3' UTR of the mature RNA. This region contains several regulatory elements (Kuersten and Goodwin, 2003) , including polyadenylation signals, AU-rich elements (Alvarez et al., 2009) , and several polymorphic sites that may potentially influence mRNA stability, turnover, mobility and splicing pattern. 3'UTR polymorphisms that can influence HLA-G expression are: i) the insertion (INS) or deletion (DEL) of a 14bp fragment (14bp INS/DEL) that has been associated with mRNA stability; ii) the SNP at position +3142, which may be a target for certain microRNAs (miRNAs), small RNA sequences which once bound to a complementary mRNA lead to its translational repression or degradation and gene silencing (Bartel, 2009) ; iii) additional six SNPs landed in putative binding sites for miRNAs (Castelli et al., 2009) (Fig.4) .
The first identified 3'UTR HLA-G polymorphism is the 14bp INS/DEL and has been studied the most. The insertion of the 14bp fragment, results in the formation of a cryptic breakpoint in the mRNA that loose the first 92bp of exon 8 (Hviid et al., 2003) . Rousseau et al. demonstrated that HLA-G transcript with the 92bp deleted seems to be more stable than the complete mRNA fragment generated by the 14bp DEL (Rousseau et al., 2003) , suggesting that 14bp INS might be associated with high levels of HLA-G expression. Nonetheless, several groups have demonstrated that 14 bp INS/INS genotype is associated with lower serum and plasma level of sHLA-G1/HLA-G5 compared to those observed in 14bp INS/DEL and 14bp DEL/DEL genotypes (Chen et al., 2008; Hviid et al., 2004; Hviid et al., 2006) , an observation that constitutes the "14bp paradox". Consistently, conflicting results have been obtained in different studies concerning the association of the 14bp HLA-G genotypes with autoimmune diseases, pathological pregnancy, recurrent spontaneous abortions, and pre-eclampsia. Notably, the presence of 14bp DEL has been found to be predictive for the incidence of GvHD after unrelated (La Nasa et al., 2007) and HLA-identical sibling (Sizzano et al., in press ) Human Stem Cell Transplantation (HSCT) for beta-thalassemia.
Several SNPs at 3'UTR of HLA-G locus have been identified (Castelli et al., 2009) . Among them, the +3142 C/G SNP has been proposed to be critically involved in HLA-G regulation since it is associated with asthma (Tan et al., 2005) . The G variant of a G/C SNP at position +3142 of the 3'UTR has been hypothesized to increase the affinity of the resulting mRNA for miR-148a, miR-148b and miR-152 (Veit and Chies, 2009) . Among these miRNAs, only miR-152 has been demonstrated responsible for HLA-G post-transcriptional regulation. Indeed, over-expression of miR-152 in JEG-3 cell lines resulted in decreasing HLA-G expression and increased susceptibility to NK cell-mediated cytolysis (Zhu et al., 2010) .
In silico analysis of the 3'UTR of the HLA-G locus revealed the presence of additional six SNPs that are landed in putative binding sites for miRNAs (Castelli et al., 2009) . Interestingly the 14bp INS/DEL and the 7 SNPs arrange in different combinations to generate eight distinct haplotypes of 3'UTR HLA-G region (Castelli et al., 2010) (Table 1) .
www.intechopen.com Therefore, it has been hypothesized that the expression of HLA-G might be influenced by a combination of specific polymorphisms. Our group is currently investigating the impact of the HLA-G 3'UTR haplotypes on HLA-G expression. Preliminary results indicate that different 3'UTR HLA-G haplotypes are associated with variable levels of HLA-G1 expression on myeloid APCs. Table 1 . 3'UTR HLA-G haplotypes
Conclusions and perspectives
Since the discovery of HLA-G, research has established its role in modulating immune responses and inducing tolerance. While a great deal of progress has been made in understanding the mechanisms underlying immune modulation by HLA-G, several questions remain to be clarified. First, HLA-G can promote the differentiation of regulatory cells and HLA-G-expressing cells act as regulatory cells, however additional studies are required to better define their role in promoting tolerance. Second, although it is generally accepted that 5' URR and 3' UTR are involved in HLA-G expression, further investigation are needed to elucidate the molecular mechanisms involved in HLA-G regulation. Third, 3'UTR HLA-G haplotypes have been identified, future studies are warranted to define whether they can influence the transcriptional rate of HLA-G isoforms and their functions. Answering these questions will not only bring us closer to understanding how HLA-G function, but also how to exploit or modulate its suppressive activity for targeted therapy against a wide variety of diseases.
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